Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
Pharmalot
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharma
STAT+

J&J to buy Momenta Pharma in a bid to bolster autoimmune disease pipeline

  • Adam Feuerstein

By Adam Feuerstein Aug. 19, 2020

Reprints
Johnson & Johnson sign
MARK RALSTON/AFP via Getty Images

Health care giant Johnson & Johnson said Wednesday that it is acquiring Momenta Pharmaceuticals, gaining access to a promising experimental treatment for autoimmune diseases.

Momenta is being acquired for $52.50 per share, or a 73% premium to Tuesday’s closing price. The all-cash deal values the company at $6.5 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

FDA report details problems at Global Pharma plant involved…
FDA report details problems at Global Pharma plant involved in eye drop recall
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Biden administration goes easy on Medicare Advantage insurers after…
Biden administration goes easy on Medicare Advantage insurers after intense industry lobbying
European Union drug pricing proposal for the pandemic treaty…
European Union drug pricing proposal for the pandemic treaty generates pushback
Inflation caused a sizable drop in net drug prices…
Inflation caused a sizable drop in net drug prices in late 2022, analysis finds

Recommended Stories